Revvity reported revenues of $729.4 million, up 4.8% year on year. This print was in line with analysts’ expectations, but overall, it was a slower quarter for the company with full-year revenue ...

Brand unveiling: While debuting its new brand at SLAS for the first time, Revvity presents its continued commitment to expanding the boundaries of human potential through science. The transformed ...

Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the ...

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, today announced a ...

Dipti Mehta has worked as a Senior Application Scientist at Revvity since 2022. Her research in DNA and protein assay development with LabChip GX Touch technology has generated new commercial assays.

Revvity (NYSE:RVTY) is preparing to release its quarterly earnings on Monday, 2026-02-02. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Revvity ...

Revvity emerged from the life sciences and diagnostics business of PerkinElmer (MA, USA) in May 2023 when the company divested its food, applied and enterprise services businesses. These businesses ...

WALTHAM, Mass.--(BUSINESS WIRE)--#LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate ...

Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position, ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to boldly unveil its new branding while showcasing more than 40 products from its life sciences and diagnostics portfolio at SLAS2024 to be held ...